Direct answers to the questions people actually search, each sourced to a named study or a disclosed count. No figure here is asserted without a citation attached, and none of them is a round, unfootnoted number lifted from a slide deck.
These are the questions clients and candidates actually ask me on calls. Three are answered in full here. Five are answered in a line, with a link to the page that carries the working.
Five questions answered in a line each. Each links to the page that carries the working, the denominators and the sources.
| Question | Short answer | Full answer |
|---|---|---|
| What percentage of FDA rejections are due to manufacturing? | No single official figure exists. CMC is the most commonly cited deficiency area at 45% of CRL'd applications later approved; across the whole published archive, 62.6% of letters carry an FDA manufacturing or quality deficiency section. | the full reconciliation of every published figure |
| How long does a Complete Response Letter delay approval? | One to two years, and the averages run longer. Median 1.28 years in one cohort, about 709 days of added delay in another, and an RSM average above 2.5 years. | the headline numbers, with sources |
| How many Complete Response Letters has the FDA published? | 459 records as of 13 August 2026, of which 446 are typed Complete Response. Publication paused in April 2026 and resumed on 10 July. | the running record and batch history |
| What's the pre-approval inspection failure rate? | The FDA does not publish one. RSM found that more than half of facility-related deficiencies in the first 200-plus released letters came from inspections the agency could not complete in time. | why the FDA does not always finish the inspection |
| Complete response letter statistics 2026: the short version | 459 published records, 62.6% carrying a manufacturing or quality deficiency section, CMC the most commonly cited category, and a median delay of one to two years. | the full statistics record |
Figures as analysed on the 22 July 2026 archive of 457 letters, with live counts verified against the openFDA API on 13 August 2026, when the archive stood at 459 records.
Chemistry, Manufacturing, and Controls (CMC), cited in 45% of CRL'd new drug applications that were later approved, ahead of efficacy (35%) and safety (21%). More than half of those letters cited more than one deficiency category, so the categories overlap rather than sum to 100%.
Source: McCarthy & O'Boyle, Drug Discovery Today (2026), 30 approved CRL'd NDAs from a 358-NDA cohort, 2013-2023.
Usually. 64% of CRL'd new drug applications in the McCarthy & O'Boyle (2026) cohort were eventually approved, 30 of 47. Recovery depends heavily on what was cited: CMC-cited CRLs were later approved 75% of the time, versus 44.4% for safety-cited CRLs. A CRL is a setback more often than it is a final verdict.
Source: McCarthy & O'Boyle, Drug Discovery Today (2026).
A warning letter is a compliance action against a facility, issued independent of any marketing application under review. A Complete Response Letter is the FDA's formal rejection of a specific NDA, BLA, or ANDA, issued only within that application's review. A site can carry warning letters for years without ever triggering a CRL, and a CRL can arrive with no warning letter in sight.
Related: regulatory violations are the #1 cited reason (26%) a CDMO loses a bid (PharmaSource survey).
| FDA warning letter | Complete Response Letter | |
|---|---|---|
| What it targets | A facility | A specific marketing application (NDA, BLA or ANDA) |
| When it can be issued | Any time, whether or not a product is under review | Only inside a review cycle, at the action date |
| What triggers it | An ongoing compliance pattern the agency wants corrected | Deficiencies that block approval of that application |
| Who it goes to | The site, including a contract manufacturer you do not own | The sponsor of the application |
| Can you have one without the other | Yes. A plant can carry warning letters for years with no CRL against it | Yes. A CRL can arrive with no warning letter, if the finding was clinical or a first-time inspection observation |
| Published by the FDA | Routinely, for years | Only since July 2025, and publication paused once already |
None of these answers will make a bad Complete Response Letter feel good. They should at least make the next board conversation about it a shorter one.
Nobody on a technical operations team can make the FDA show up on schedule. What experience changes is the odds of passing once they do. Phase 3 Search places the CMC, quality, and technical operations leaders who have walked a plant through that inspection before.
Start the conversation →